Molecular Neurodegeneration 2013-01-01

Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.

Miguel M Carvalho, Filipa L Campos, Bárbara Coimbra, José M Pêgo, Carla Rodrigues, Rui Lima, Ana J Rodrigues, Nuno Sousa, António J Salgado

Index: Molecular Neurodegeneration 8 , 14, (2013)

Full Text: HTML

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative condition that is characterized by motor symptoms as a result of dopaminergic degeneration, particularly in the mesostriatal pathway. However, in recent years, a greater number of clinical studies have focused on the emergence of non-motor symptoms in PD patients, as a consequence of damage on the mesolimbic and mesocortical dopaminergic networks, and on their significant impact on the quality of life of PD patients. Herein, we performed a thorough behavioral analysis including motor, emotional and cognitive dimensions, of the unilateral medial forebrain bundle (MFB) 6-hydroxidopamine (6-OHDA)-lesioned model of PD, and further addressed the impact of pharmacological interventions with levodopa and antidepressants on mood dimensions.Based on apomorphine-induced turning behaviour and degree of dopaminergic degeneration, animals submitted to MFB lesions were subdivided in complete and incomplete lesion groups. Importantly, this division also translated into a different severity of motor and exploratory impairments and depressive-like symptoms; in contrast, no deficits in anxiety-like and cognitive behaviors were found in MFB-lesioned animals. Subsequently, we found that the exploratory and the anhedonic behavioural alterations of MFB-lesioned rats can be partially improved with the administration of both levodopa or the antidepressant bupropion, but not paroxetine.Our results suggest that this model is a relevant tool to study the pathophysiology of motor and non-motor symptoms of PD. In addition, the present data shows that pharmacological interventions modulating dopaminergic transmission are also relevant to revert the non-motor behavioral deficits found in the disease.


Related Compounds

  • Paroxetine maleate
  • 6-HYDROXYDOPA...
  • Paroxetine hydroch...
  • bupropion hydrochl...

Related Articles:

A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.

2013-02-01

[J. Clin. Psychopharmacol. 33(1) , 3-10, (2013)]

Chronic angle-closure glaucoma related to paroxetine treatment.

2013-07-01

[Semin. Ophthalmol. 28(4) , 244-6, (2013)]

Paroxetine (Brisdelle) for hot flashes.

2013-10-28

[Med. Lett. Drugs Ther. 55(1428) , 85-6, (2013)]

FDA Approval of Paroxetine for Menopausal Hot Flushes

2014-05-08

[N. Engl. J. Med. 370(19) , 1777-9, (2014)]

Serotonin and yawning: a potential adverse drug reaction during antidepressant therapy

2013-10-16

[Presse Med. 43(10 Pt 1) , 1135-6, (2014)]

More Articles...